Young streak off a low base: a short run of consecutive-period improvement has just started, after a stretch that gave i
The model's full reasoning — Q1 2024 call → NO我们根据提供的财报电话会议记录来判断。问题问的是管理层是否传达了一个“短而年轻的连续改善期”的故事,包含三个要素:先前不令人印象深刻的时期、连续的改善、以及公司自身原因仍在起作用。 在记录中,管理层提到了多个方面的改善。例如,Jim Clemmer说:“我们很高兴看到在第一季度我们在几个领域看到了改善,尽管还有更多工作要做。”他提到MedTech增长13%,NanoKnife增长36%,国际业务增长26%,Auryon增长26%等。但问题特别关注的是“一个部分”的业务,且是“连续几个时期”的改善。 具体看,关于AngioVac,管理层说:“我们受到鼓舞的是,AngioVac收入虽然同比下降,但环比增长,我们相信我们正在采取的措施正在获得积极牵引。”这里提到了环比增长,但只有一季度,没有连续多个季度。关于机械血栓切除业务,整体下降6%,但AngioVac环比增长。 关于NanoKnife,增长强劲,但这是长期趋势,不是从弱转强的年轻改善。 关于Auryon,增长26%,但也是持续增长。 问题要求的是“roughly two to four periods in a row of getting better”在一个之前不令人印象深刻的业务部分。在记录中,管理层提到AngioVac在Q2和Q3 fiscal 2023面临挑战,现在正在稳定和反弹。Steve Trowbridge说:“AngioVac continues to stabilize and rebound from the challenges we faced in Q2 and Q3 of fiscal '23, and we continue to take meaningful steps to address those challenges... AngioVac revenue was $6.3 million in the quarter, representing a decline of 7.7% over the prior year, but up sequentially from the fourth quarter and trending in the right direction.” 这里明确说环比增长,但只有一季度(Q1 FY24 vs Q4 FY23),没有连续多个季度。而且同比仍下降。 关于整个公司,管理层说“solid start financially against our fiscal year goals”,但整体是亏损,调整后EPS为-0.13,比去年同期的-0.15略好,但仍是亏损。没有连续改善的表述。 关于MedTech整体,增长13%,但这是同比,没有说连续几个季度。 因此,没有找到管理层明确描述一个“连续两到四个时期改善”的年轻运行。只有AngioVac的环比增长,但只有一次,且同比仍下降。其他业务都是持续增长,不是从弱转强。 所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| OLPX | Olaplex Holdings, Inc. | Q4 2023 | 2024-02-29 | D |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LEG | Leggett & Platt, Incorporated | Q3 2021 | 2021-11-02 | C |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
WRBY · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
ASB · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
KOPN · Q4 2023 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...